Somewhat Positive News Coverage Somewhat Unlikely to Affect Impax Laboratories (IPXL) Stock Price

News headlines about Impax Laboratories (NASDAQ:IPXL) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Impax Laboratories earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.503140015714 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s rankings:

Shares of Impax Laboratories stock remained flat at $$19.45 on Thursday. The stock had a trading volume of 929,978 shares, compared to its average volume of 983,906. Impax Laboratories has a 1-year low of $11.85 and a 1-year high of $25.70. The firm has a market capitalization of $1,426.97, a P/E ratio of -2.98, a PEG ratio of 0.82 and a beta of 1.01. The company has a debt-to-equity ratio of 4.11, a quick ratio of 1.52 and a current ratio of 1.96.

Impax Laboratories (NASDAQ:IPXL) last announced its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 EPS for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.01). The company had revenue of $182.90 million for the quarter, compared to analyst estimates of $199.13 million. Impax Laboratories had a positive return on equity of 10.42% and a negative net margin of 60.49%. The business’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.16 earnings per share. analysts forecast that Impax Laboratories will post 1.27 EPS for the current year.

IPXL has been the subject of several research reports. Cantor Fitzgerald set a $35.00 target price on Impax Laboratories and gave the company a “buy” rating in a research report on Friday, December 15th. Leerink Swann initiated coverage on Impax Laboratories in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 target price for the company. BidaskClub downgraded Impax Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, February 16th. Zacks Investment Research raised Impax Laboratories from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Finally, Guggenheim initiated coverage on Impax Laboratories in a research report on Tuesday, December 12th. They issued a “neutral” rating and a $18.00 target price for the company. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. Impax Laboratories currently has a consensus rating of “Hold” and a consensus price target of $20.91.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Impax Laboratories (IPXL) Stock Price” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/2018/03/29/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-impax-laboratories-ipxl-stock-price/1971592.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Insider Buying and Selling by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.